Organon (OGN) Q4 2025 earnings review
Governance Clouds Darken a Weak Quarter
Organon closed 2025 with a messy quarter characterized by a $301 million goodwill impairment, a new internal investigation into biosimilar purchasing, and a 20% ex-FX drop in its flagship Nexplanon franchise. While management points to 'policy changes' and 'wholesaler practices' for the U.S. weakness, the narrative is strained. Revenue fell 5% reported, and Adjusted EBITDA margins compressed significantly to 25.4%. Guidance for 2026 is effectively stagnant (flat revenue and EBITDA), implying that any growth from new launches will merely plug the holes left by pricing pressure and divestitures.
🐂 Bull Case
The Biosimilars segment remains a bright spot, growing 11% in Q4 driven by Hadlima (+60% FY). With new launches (denosumab) and acquired assets (Tofidence), this segment is successfully offsetting declines in mature products.
Management is prioritizing balance sheet repair. The Jada system divestiture (completed Jan 2026) and cash flow generation are expected to push net leverage below 4.0x by year-end 2026, improving financial flexibility.
🐻 Bear Case
Just months after an investigation into Nexplanon sales practices, a new issue regarding 'timing of biosimilars purchases' has triggered an Audit Committee review. Coupled with a CEO transition, this raises serious questions about internal controls.
Organon's primary growth engine stalled in its biggest market. U.S. Nexplanon sales are being hit by wholesaler destocking and funding constraints at clinics. Management's expectation for flat 2026 performance implies no near-term V-shaped recovery.
⚖️ Verdict: 🔴
Bearish. The combination of a new audit investigation, a massive impairment charge, and shrinking margins outweighs the modest success in Biosimilars. 2026 guidance suggests a year of stagnation rather than recovery.
Key Themes
New Governance Red Flag: Biosimilars
On February 11, 2026, a new issue was brought to the Audit Committee regarding the 'timing of purchases of biosimilars from a supplier.' While management states no financial restatements are currently anticipated, this follows closely on the heels of the Q3 investigation into improper Nexplanon sales practices. Two internal investigations in two quarters suggests a potential systemic culture or control issue.
Nexplanon U.S. Collapse
Decelerating. Nexplanon, the company's flagship, saw global sales fall 20% Ex-FX in Q4. The U.S. market is the problem: sales were impacted by the cessation of 'identified wholesaler sales practices' (a $17M hit) and policy-related access restrictions. While International grew, it could not offset the U.S. decline. The 5-year indication approval is a positive, but the immediate volume trend is alarming.
Gross Margin Erosion
Decelerating. Adjusted Gross Margin fell significantly to 56.7% in Q4 from 60.6% a year ago. Management cites unfavorable pricing, FX, and product mix. More concerning is the 2026 guidance, which calls for another 75-100 bps decline from FY25 levels (60.1%), signaling that pricing power is weak.
Biosimilars Momentum (Hadlima)
Accelerating. The Biosimilars franchise grew 11% in Q4. Hadlima (Humira biosimilar) is the standout, growing 60% in FY25. Along with new launches like Tofidence and upcoming denosumab biosimilars, this segment is doing the heavy lifting to offset declines elsewhere.
Goodwill Impairment
The company recorded a massive $301 million non-cash goodwill impairment in Q4 related to 'underperformance of several products in the U.S.' This charge wiped out GAAP profitability for the quarter (Net Loss $205M) and signals management's reduced long-term expectations for the U.S. portfolio.
Vtama & Dermatology
Stable. Vtama (acquired from Dermavant) contributed $128M in FY25 revenue (pro-forma/combined). While meaningful, it is expensive to support. Management expects growth in 2026, but it must fight against a backdrop of pricing pressure in the broader portfolio.
Other KPIs
Stable. Despite earnings pressure, cash generation remains robust (flat vs FY24). This is critical for the deleveraging thesis. However, free cash flow in 2026 is expected to be flat again due to higher CapEx and working capital needs.
Stable. Leverage remains high. The company retired $530M of debt in 2025. With $390M proceeds from the Jada divestiture coming in Q1 26, management targets <4.0x by end of 2026. This is a slow grind.
Decelerating. A sharp drop from 28.1% in the prior year and 32.3% in Q3. This compression driven by gross margin weakness was only partially offset by OpEx cuts.
Guidance
Stable. Guidance implies flat reported growth and ~1.5% decline Ex-FX vs FY25. It reflects the loss of Jada revenue (divested), offset by modest FX tailwinds. Essentially a zero-growth year.
Stable. In line with FY25 performance ($1.91B). Management is relying on cost cuts (SG&A mid-20% range) to defend EBITDA dollars as gross margins contract.
Decelerating. Guidance is for margins to be 75-100 bps lower than 2025 (60.1%). This continues a multi-year downward trend in profitability per unit.
Accelerating (Bad). A significant jump from 24.4% in 2025 due to Pillar 2 global minimum tax implementation. This will be a direct headwind to EPS.
Key Questions
Scope of Audit Investigation
Regarding the new review into biosimilar purchasing timing: Is this limited to a single supplier or region? Does it risk restatement of prior period inventory or COGS?
Nexplanon U.S. Recovery
With the 5-year indication approved but volume down 20% in Q4, is the 'cessation of sales practices' a one-time reset, or was true demand artificially inflated for longer than acknowledged?
Margin Floor
Gross margins are guided down again for 2026. At what point does the mix shift to Biosimilars (lower margin) and established brands erosion stabilize? Is sub-60% the new normal?
Impairment Specifics
The $301M impairment cited 'underperformance of several products in the U.S.' Which specific assets were written down, and does this change the peak sales outlook for Vtama or other recent acquisitions?